SAVE THE DATE

Be sure to mark your calendars!

2016 Fall Meeting
Renaissance Arts Hotel in New Orleans
September 30 - October 01, 2016

More details coming soon!

Find a Psychiatrist

image

Resources for the Public

image

Calendar of Events

image

Newsletters

image

Spring Meeting Highlights


Mississippi Exec Angela Ladner with friends and members pausing for the peanut butter and jelly sandwiches and hot chocolate provided by the hotel each night!  Yummy!! 

Dr. Dean Robinson receives special thanks from the membership for two great years of service as President

Dr. Lee Stevens is given appreciation for his service as Past President

Dr.  Lee Michals receives LSU Shreveport Excellence in Psychiatry Award for Graduating Residents-Fellows

Dr. Jill McCall is awarded the Resident-Fellow LSU New Orleans Excellence in Psychiatry Award

Dr. Veronique Haymon receives the Tulane Resident-Fellow Excellence in Psychiatry Award 

Not pictured is Dr. Jason Boudreaux who received the Resident-Fellow LSU Baton Rouge Excellence in Psychiatry Award.  Congratulations to all!

Latest News

Psychiatric News Alert

The Voice of the American Psychiatric Association and the Psychiatric Community
  • Quetiapine Appears Effective as Monotherapy for PTSD, Study Shows

    The atypical antipsychotic quetiapine appears to be effective as a single agent in the treatment of posttraumatic stress disorder (PTSD), according to a report in AJP in Advance.

    Not all patients with PTSD respond to first-line antidepressant treatment, and current VA/Department of Defense guidelines recommend quetiapine and other antipsychotic medications as adjunctive treatments. Researchers from several VA centers and research institutions sought to determine the efficacy of quetiapine as monotherapy.

    Eighty veterans meeting criteria for chronic PTSD were randomly assigned to treatment with either quetiapine or placebo tablets for 12 weeks. Quetiapine was initiated at a dose of 25 mg at bedtime and gradually titrated up to a minimum of 50 mg and maximum of 800 mg daily. The participants were evaluated at weeks 1, 2, 4, 8, and 12.

    The primary outcome measure was the total Clinician-Administered PTSD Scale (CAPS) score. Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A).

    Patients in the quetiapine group experienced greater reductions in CAPS total, re-experiencing, and hyperarousal scores than those in the placebo group. (Scores on the CAPS avoidance/numbing subscale and the PANSS negative symptom subscale did not differ from those of the placebo...